No Data
Express News | Neurocrine Biosciences Inc : RBC Cuts Target Price to $154 From $159
Neurocrine Announced Publication Of Supplement On Classic Congenital Adrenal Hyperplasia In The Journal Of Clinical Endocrinology & Metabolism, Covering Clinical, Psychosocial, Treatment Challenge
Neurocrine Biosciences Insider Sold Shares Worth $9,197,550, According to a Recent SEC Filing
Neurocrine Biosciences(NBIX.US) Officer Sells US$9.2 Million in Common Stock
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192
Express News | Form 144 | Neurocrine Biosciences(NBIX.US) Officer Proposes to Sell 9.07 Million in Common Stocks
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50
Srav Reddy : You missed VSTM and